tiprankstipranks
Trending News
More News >
Balaji Amines Limited (IN:BALAMINES)
:BALAMINES
India Market
Advertisement

Balaji Amines Limited (BALAMINES) AI Stock Analysis

Compare
4 Followers

Top Page

IN:BALAMINES

Balaji Amines Limited

(BALAMINES)

Select Model
Select Model
Select Model
Neutral 59 (OpenAI - 4o)
Rating:59Neutral
Price Target:
₹1,634.00
▲(19.92% Upside)
Balaji Amines has a strong financial foundation but faces challenges in revenue growth. Technical indicators point to bearish momentum, with the stock trading below key moving averages. The valuation metrics indicate the stock may be overvalued, creating a cautious outlook unless growth prospects improve.

Balaji Amines Limited (BALAMINES) vs. iShares MSCI India ETF (INDA)

Balaji Amines Limited Business Overview & Revenue Model

Company DescriptionBalaji Amines Limited engages in the manufacture and sale of methylamines, ethylamines, and derivatives of specialty chemicals and pharma excipients in India. The company operates through three segments: Amines & Speciality Chemicals, Hotel, and CFL Lamps. It offers monomethylamine, dimethylamine, trimethylamine, monoethylamine, diethylamine, triethylamine, dimethyl and diethyl amino ethanol; and specialty chemicals, including N-methyl pyrrolidone, morpholine, 2-pyrrolidone, N-ethyl-2-pyrrolidone, gamma-butyrolactone, dimethylformamide, and acetonitrile. The company also provides derivatives comprising di-methyl acetamide, di-methyl amine hydrochloride, tri-methyl amine hydrochloride, di-ethyl amine hydrochloride, tri-ethyl amine hydrochloride, di-methyl urea, and choline chloride; and pharma excipients, such as poly vinyl pyrrolidone. It serves pharmaceutical, agrochemical, paint and resin, animal feed, oil and gas, rubber cleaning chemical, dye and textile, and water treatment chemical industries. In addition, the company operates Balaji Sarovar, a hotel in Solapur, Maharashtra; and manufactures and sells CFL lamps. It also exports its products to the United States, Europe, China, Turkey, Korea, Malaysia, Kuwait, and internationally. The company was incorporated in 1988 and is based in Hyderabad, India.
How the Company Makes MoneyBalaji Amines generates revenue through the production and sale of its specialty chemicals, particularly amines and their derivatives. The company has established a strong revenue model based on a diverse customer base spanning multiple industries, including pharmaceuticals, agrochemicals, and personal care. Key revenue streams include the sale of high-demand products such as methylamines and ethylamines, which are utilized in numerous applications from drug manufacturing to agricultural chemicals. Additionally, BALAMINES benefits from long-term partnerships with major players in its target sectors, ensuring consistent demand for its products. The company also focuses on research and development to innovate and expand its product offerings, further enhancing its market position and revenue potential.

Balaji Amines Limited Financial Statement Overview

Summary
Balaji Amines is financially sound with a stable balance sheet and consistent cash flow generation. The company has maintained profitability despite revenue pressures, signaling good operational efficiency. To ensure long-term growth, management should address revenue challenges and continue to optimize cash flow.
Income Statement
76
Positive
Balaji Amines has shown resilience in its income statement despite revenue fluctuations. The Gross Profit Margin and Net Profit Margin have been reasonably stable, reflecting effective cost management. However, the recent contraction in revenue and net income suggests challenges in market conditions or competition.
Balance Sheet
82
Very Positive
The balance sheet is strong, with a low Debt-to-Equity Ratio indicating conservative financial leverage. The equity ratio is robust, showcasing a solid capital structure. However, the company should watch for any increase in liabilities that could affect its financial stability.
Cash Flow
79
Positive
Cash flow metrics reveal effective cash management, with positive Free Cash Flow indicating the ability to sustain operations and investments. While the Operating Cash Flow to Net Income ratio is healthy, the company must focus on improving cash flow growth to support future expansions.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue13.71B13.97B16.08B23.38B23.20B13.11B
Gross Profit5.59B4.88B3.50B8.39B8.57B5.39B
EBITDA2.55B2.65B3.53B6.24B6.36B3.79B
Net Income1.52B1.58B2.05B3.26B3.68B2.38B
Balance Sheet
Total Assets0.0022.52B21.46B19.63B18.75B13.10B
Cash, Cash Equivalents and Short-Term Investments3.50B3.50B3.31B3.09B515.37M173.23M
Total Debt0.00110.27M196.97M575.74M1.01B1.27B
Total Liabilities-20.18B2.34B2.53B2.65B5.60B4.00B
Stockholders Equity20.18B18.45B17.22B15.54B12.50B8.94B
Cash Flow
Free Cash Flow0.00874.82M704.14M2.62B842.07M-221.07M
Operating Cash Flow0.002.73B3.34B3.82B2.32B1.10B
Investing Cash Flow0.00-1.61B-1.64B-1.86B-1.47B-615.89M
Financing Cash Flow0.00-447.73M-749.66M-812.33M-565.13M-374.51M

Balaji Amines Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1362.60
Price Trends
50DMA
1473.72
Negative
100DMA
1553.30
Negative
200DMA
1495.76
Negative
Market Momentum
MACD
-38.45
Negative
RSI
34.91
Neutral
STOCH
37.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BALAMINES, the sentiment is Negative. The current price of 1362.6 is below the 20-day moving average (MA) of 1404.87, below the 50-day MA of 1473.72, and below the 200-day MA of 1495.76, indicating a bearish trend. The MACD of -38.45 indicates Negative momentum. The RSI at 34.91 is Neutral, neither overbought nor oversold. The STOCH value of 37.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BALAMINES.

Balaji Amines Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
₹37.14B27.180.07%15.47%-1.72%
62
Neutral
₹38.43B114.230.07%11.14%-11.15%
62
Neutral
₹98.23B52.620.52%10.29%26.09%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
59
Neutral
₹44.15B29.000.81%-12.28%-22.10%
57
Neutral
₹120.80B77.760.07%69.32%113.55%
54
Neutral
₹9.96B107.160.98%-19.46%-80.73%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:BALAMINES
Balaji Amines Limited
1,362.60
-766.14
-35.99%
IN:ALKYLAMINE
Alkyl Amines Chemicals Limited
1,920.75
-244.87
-11.31%
IN:ANURAS
Anupam Rasayan India Ltd.
1,061.05
336.57
46.46%
IN:FAIRCHEMOR
Fairchem Organics Ltd
770.85
-361.68
-31.94%
IN:NEOGEN
Neogen Chemicals Ltd.
1,456.60
-518.49
-26.25%
IN:ROSSARI
Rossari Biotech Ltd
670.80
-159.42
-19.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 05, 2025